Fremont, Calif. January 20, 2010 – Zosano Pharma, Inc., a privately held pharmaceutical company developing products based on its novel transdermal delivery technology, today announced that Dr. Peter Daddona, the company’s chief scientific officer, will present at the 14th Annual Drug Delivery Partnerships Meeting in Orlando, Florida on Tuesday, January 26 at 11:30 AM.
Dr. Daddona will present as part of a Technology Showcase Spotlight highlighting next generation technologies. The presentation, titled “Zosano’s Drug-coated Microneedle Patch: Advancing Products to Commercial” will focus on the company’s lead product, the ZP rapid delivery patch, a Phase 3 ready product in development for the treatment of osteoporosis in postmenopausal women. ZP-PTH, uses the company’s unique transdermal technology, being developed as an alternative to daily injections, to deliver PTH 1-34, teriparatide, a compound that has been proven to stimulate formation of new bone and reduce the risk of fractures.
The presentation will also discuss the company’s successful Phase 1 flu vaccine study, other pipeline products and recent advances in manufacturing capabilities.
About Zosano Pharma
Zosano Pharma, Inc. is a privately held pharmaceutical company developing products based on its novel transdermal delivery technology for a broad range of therapeutic indications. Its lead clinical program, the ZP-PTH rapid delivery patch for the treatment of osteoporosis, is being developed as an alternative to daily injections. The company’s transdermal delivery technology is capable of delivering peptides, proteins, small molecules and vaccines by permeating the skin's outer layer and ensuring significant therapeutic effect. This proven proprietary technology offers several key benefits, including efficacy and safety comparable to approved injectables, needle-free delivery, a self-administered patch, rapid onset of action and room temperature storage. Zosano's transdermal delivery technology has been clinically tested in over 400 patients with four different peptides and a vaccine. Zosano aims to develop products both independently and through strategic licensing and co-development arrangements. Founded in 2006 as an ALZA Corporation spin-out led by Nomura Phase4 Ventures, Zosano has raised $120 million and is funded by New Enterprise Associates, Nomura Phase4 Ventures, HBM BioVentures and ProQuest Investments. For more information, please visit www.zosanopharma.com.